Table 2 Characteristics of patients according to outcome
Variables | Total (n = 170) | Without (n = 131) | With (n = 39) | P |
|---|---|---|---|---|
Age (day), M (IQR) | 84 (49, 151) | 85 (48, 141) | 71 (51, 192) | 0.732 |
Gender (male), n(%) | 90 (52.94) | 73 (55.73) | 17 (43.59) | 0.183 |
Immunization, n(%) | 76 (44.71) | 59 (45.04) | 17 (43.59) | 0.873 |
WBC (× 109/l),M (IQR) | 32.77 (17.68, 58.25) | 25.42 (15.38, 42.33) | 66.12 (55.26, 83.10) | <.001 |
Lymphocytic absolute value, M (IQR) | 15.18 (7.68, 27.20) | 12.11 (6.14, 21.66) | 28.22 (23.40, 37.78) | <.001 |
Neutrophils absolute value, M (IQR) | 13.62 (7.20, 23.83) | 10.26 (6.29, 16.92) | 27.57 (20.33, 39.46) | <.001 |
Monocytes absolute value, M (IQR) | 1.44 (0.73, 2.80) | 1.09 (0.66, 1.94) | 2.84 (2.12, 4.57) | <.001 |
PLT (× 109/l), M (IQR) | 565(466, 708) | 548 (446, 690) | 620 (527, 743) | 0.064 |
CRP (mg/l), M (IQR) | 8 (8, 22) | 8 (8, 15) | 18 (8, 34) | 0.001 |
PCT (ng/ml), M (IQR) | 0.11 (0.07, 0.31) | 0.11 (0.07, 0.30) | 0.13 (0.08, 0.33) | 0.278 |
Bilirubin (μmol/l), M (IQR) | 6.50 (2.00, 13.68) | 7.00 (2.00, 13.55) | 6.30 (3.00, 13.15) | 0.956 |
Creatinine (μmol/l), M (IQR) | 21.50 (17.52, 25.48) | 22.00 (18.00, 25.75) | 21.00 (16.00, 25.20) | 0.162 |
ALT (U/L), M (IQR) | 34.00 (23.85, 47.00) | 35.60 (26.25, 48.15) | 30.60 (19.50, 42.70) | 0.029 |
PCO2(mmHg), M (IQR) | 43.30 (37.00, 52.00) | 43.00 (36.50, 50.25) | 49.00 (40.40, 55.05) | 0.03 |
PO2(mmHg), M (IQR) | 86.40 (65.03, 118.50) | 89.10 (67.35, 124.50) | 78.20 (61.50, 97.20) | 0.142 |
PH, n(%) | 18 (10.59) | 15 (11.45) | 3 (7.69) | 0.709 |
Epilepsy, n(%) | 8 (4.71) | 5 (3.82) | 3 (7.69) | 0.567 |
Hypoproteinemia, n(%) | 74 (43.53) | 58 (44.27) | 16 (41.03) | 0.719 |
Sepsis, n(%) | 27 (15.88) | 21 (16.03) | 6 (15.38) | 0.923 |
Shock, n(%) | 32 (18.82) | 13 (9.92) | 19 (48.72) | <.001 |
Respiratory failure, n(%) | 164 (96.47) | 127 (96.95) | 37 (94.87) | 0.903 |
ARDS, n(%) | 12 (7.06) | 9 (6.87) | 3 (7.69) | 1.000 |
Myocardial injury, n(%) | 50 (29.41) | 34 (25.95) | 16 (41.03) | 0.070 |
ECMO, n(%) | 3 (1.76) | 3 (2.29) | 0 (0.00) | 1.000 |
Hepatic injury, n(%) | 34 (20.00) | 29 (22.14) | 5 (12.82) | 0.202 |
AKI, n(%) | 9 (5.29) | 6 (4.58) | 3 (7.69) | 0.723 |
Other respiratory pathogen infectionsa, n(%) | 129 (75.88) | 100 (76.34) | 29 (74.36) | 0.800 |
Pneumonia, n(%) | 165 (97.06) | 128 (97.71) | 37 (94.87) | 0.703 |
Atelectasis, n(%) | 66 (38.82) | 54 (41.22) | 12 (30.77) | 0.240 |
Lung consolidation, n(%) | 121 (71.18) | 90 (68.70) | 31 (79.49) | 0.192 |
Vasoactive drugs, n(%) | 98 (57.65) | 69 (52.67) | 29 (74.36) | 0.016 |
Albumin, n(%) | 124 (72.94) | 86 (65.65) | 38 (97.44) | <.001 |
Hormones, n(%) | 98 (57.65) | 78 (59.54) | 20 (51.28) | 0.359 |
IVIG, n(%) | 110 (64.71) | 86 (65.65) | 24 (61.54) | 0.637 |
Ventilator, n(%) | 155 (91.18) | 117 (89.31) | 38 (97.44) | 0.212 |
High frequency ventilation, n(%) | 11 (6.47) | 6 (4.58) | 5 (12.82) | 0.143 |
Invasive ventilation, n(%) | 142 (83.53) | 106 (80.92) | 36 (92.31) | 0.092 |
Mortality,n (%) | 38 (22.35) | 22 (16.79) | 16 (41.03) | 0.001 |